Search

Your search keyword '"Desai, Akshay S"' showing total 1,488 results
Start Over "Desai, Akshay S"
1,488 results on '"Desai, Akshay S"'

101. Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction

Author

Vardeny, Orly, primary, Desai, Akshay S., additional, Jhund, Pardeep S., additional, Fang, James C., additional, Claggett, Brian, additional, de Boer, Rudolf A., additional, Hernandez, Adrian F., additional, Inzucchi, Silvio E., additional, Kosiborod, Mikhail N., additional, Lam, Carolyn S. P., additional, Martinez, Felipe A., additional, Shah, Sanjiv J., additional, Mc Causland, Finnian R., additional, Petrie, Mark C., additional, Vaduganathan, Muthiah, additional, McMurray, John J. V., additional, and Solomon, Scott D., additional

Published
2024
Full Text
View/download PDF

102. A Single Center Experience Of 480 Intravenous Iron Infusions In An Outpatient Heart Failure Clinic

Author

Albuloushi, Asmaa, primary, Buckley, Leo F., additional, Young, Michelle A., additional, Weintraub, Joanne R., additional, Forgeron, Christine, additional, Molway, David W., additional, Palmer, Denise, additional, Shea, Elaine L., additional, Melanson, Francis, additional, Kim, Ju Hee, additional, Kociol, Kristin, additional, Velez, Kristina, additional, Pimentel, Liriany Y., additional, Zaria, Mohsen Al, additional, Alkhezi, Omar Saleh B, additional, Matta, Lina S., additional, and Desai, Akshay S., additional

Published
2024
Full Text
View/download PDF

103. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial

Author

Vardeny, Orly, Claggett, Brian, Packer, Milton, Zile, Michael R, Rouleau, Jean, Swedberg, Karl, Teerlink, John R, Desai, Akshay S, Lefkowitz, Martin, Shi, Victor, McMurray, John JV, Solomon, Scott D, and Investigators, for the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure

Subjects
Clinical Trials and Supportive Activities, Clinical Research, Cardiovascular, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Aged, Aminobutyrates, Angiotensin Receptor Antagonists, Biphenyl Compounds, Dose-Response Relationship, Drug, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Humans, Male, Middle Aged, Stroke Volume, Tetrazoles, Valsartan, Chronic heart failure, Neprilysin inhibitor, Clinical trial, Sacubitril, Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Investigators, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology
Abstract

AimsIn this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants who exhibited any dose reduction during the trial would have similar benefits from lower doses of sacubitril/valsartan relative to lower doses of enalapril.Methods and resultsIn a post-hoc analysis from PARADIGM-HF, we characterized patients by whether they received the maximal dose (200 mg sacubitril/valsartan or 10 mg enalapril twice daily) throughout the trial or had any dose reduction to lower doses (100/50/0 mg sacubitril/valsartan or 5/2.5/0 mg enalapril twice daily). The treatment effect for the primary outcome was estimated, stratified by dose level using time-updated Cox regression models. In the two treatment arms, participants with a dose reduction (43% of those randomized to enalapril and 42% of those randomized to sacubitril/valsartan) had similar baseline characteristics and similar baseline predictors of the need for dose reduction. In a time-updated analysis, any dose reduction was associated with a higher subsequent risk of the primary event [hazard ratio (HR) 2.5, 95% confidence interval (CI) 2.2-2.7]. However, the treatment benefit of sacubitril/valsartan over enalapril following a dose reduction was similar (HR 0.80, 95% CI 0.70-0.93, P < 0.001) to that observed in patients who had not experienced any dose reduction (HR 0.79, 95% CI 0.71-0.88, P < 0.001).ConclusionsIn PARADIGM-HF, study medication dose reduction identified patients at higher risk of a major cardiovascular event. The magnitude of benefit for patients on lower doses of sacubitril/valsartan relative to those on lower doses of enalapril was similar to that of patients who remained on target doses of both drugs.

Published
2016

104. Independent prognostic importance of blood urea nitrogen (BUN) to creatinine ratio in heart failure

Author

Tolomeo, Paolo, primary, Butt, Jawad H, additional, Kondo, Toru, additional, Campo, Gianluca, additional, Desai, Akshay S., additional, Jhund, Pardeep S, additional, Køber, Lars, additional, Lefkowitz, Martin P., additional, Rouleau, Jean L., additional, Solomon, Scott D., additional, Swedberg, Karl, additional, Vaduganathan, Muthiah, additional, Zile, Michael R., additional, Packer, Milton, additional, and McMurray, John JV, additional

Published
2023
Full Text
View/download PDF

105. Natural Language Processing for Adjudication of Heart Failure in a Multicenter Clinical Trial

Author

Cunningham, Jonathan W., primary, Singh, Pulkit, additional, Reeder, Christopher, additional, Claggett, Brian, additional, Marti-Castellote, Pablo M., additional, Lau, Emily S., additional, Khurshid, Shaan, additional, Batra, Puneet, additional, Lubitz, Steven A., additional, Maddah, Mahnaz, additional, Philippakis, Anthony, additional, Desai, Akshay S., additional, Ellinor, Patrick T., additional, Vardeny, Orly, additional, Solomon, Scott D., additional, and Ho, Jennifer E., additional

Published
2023
Full Text
View/download PDF

106. Abstract 12470: Sacubitril/Valsartan in Patients With Heart Failure and Deterioration of Kidney Function to Estimated Glomerular Filtration Rate Less Than 30ml/min/1.73m 2 : Insights From PARAGON-HF and PARADIGM-HF

Author

Chatur, Safia, primary, Vaduganathan, Muthiah, additional, Claggett, Brian L, additional, McCausland, Finnian, additional, Desai, Akshay S, additional, Beldhuis, Iris, additional, Rouleau, Jean L, additional, Zile, Michael R, additional, Packer, Milton, additional, Pfeffer, Marc A, additional, Lefkowitz, Martin P, additional, McMurray, John J, additional, and Solomon, Scott D, additional

Published
2023
Full Text
View/download PDF

118. Sex Differences in Heart Failure With Improved Ejection Fraction

Author

Pabón, Maria A., Wang, Xiaowen, Lam, Carolyn S.P., O’Meara, Eileen, Vaduganathan, Muthiah, Claggett, Brian L., Foà, Alberto, Lu, Henri, Langkilde, Anna Maria, De Boer, Rudolf A., Desai, Akshay S., Hernandez, Adrian F., Inzucchi, Silvio E., Jhund, Pardeep S., Kosiborod, Mikhail N., Martinez, Felipe A., Shah, Sanjiv J., Petersson, Magnus, McMurray, John J.V., Solomon, Scott D., and Vardeny, Orly

Published
2024
Full Text
View/download PDF

119. Innovative Approaches in the Treatment and Management of Heart Failure: Managed Care Considerations on the Role of New and Emerging Therapies.

Author

Desai, Akshay S.

Subjects
PREVENTIVE medicine, CONTINUING education units, MANAGED care programs, VENTRICULAR ejection fraction, DIFFUSION of innovations, MEDICAL care, HOSPITAL care, HEART failure, CAUSES of death, ANGIOTENSIN receptors, MINERALOCORTICOIDS, PROTEOLYTIC enzymes, ADRENERGIC beta blockers, SODIUM-glucose cotransporter 2 inhibitors, CARDIOVASCULAR agents, CELL receptors, DISEASE complications, CHEMICAL inhibitors, SYMPTOMS
Abstract

The management of heart failure has changed significantly over the past few years. Based on recent trials, a four-medication strategy is recommended for those with reduced ejection fraction and a newer therapy is recommended for those with preserved ejection fraction. The recommended agents have been shown to reduce morbidity, mortality, and especially hospitalizations related to heart failure. [ABSTRACT FROM AUTHOR]

Published
2024

120. RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial.

Author

Bakris, George L., Saxena, Manish, Gupta, Anil, Chalhoub, Fadi, Lee, Jongtae, Stiglitz, Daniel, Makarova, Nune, Goyal, Nitender, Guo, Weinong, Zappe, Dion, and Desai, Akshay S.

Subjects
RNA interference, AMBULATORY blood pressure monitoring, SMALL interfering RNA, SYSTOLIC blood pressure, CLINICAL trials, BLOOD pressure
Abstract

Key Points: Question: Does targeting hepatic angiotensinogen synthesis with the RNA interference therapeutic zilebesiran reduce blood pressure in adults with mild to moderate hypertension? Findings: In a phase 2 trial, subcutaneous zilebesiran doses of 150, 300, or 600 mg every 6 months or 300 mg every 3 months significantly decreased systolic blood pressure at 3 and 6 months vs placebo. Nonserious drug-related adverse events occurred in 16.9% of zilebesiran-treated patients, principally injection site reactions and mild hyperkalemia. Meaning: Single subcutaneous doses of zilebesiran significantly lower blood pressure for up to 6 months, suggesting potential for use as an effective antihypertensive with quarterly or biannual dosing. Importance: Angiotensinogen is the most upstream precursor of the renin–angiotensin–aldosterone system, a key pathway in blood pressure (BP) regulation. Zilebesiran, an investigational RNA interference therapeutic, targets hepatic angiotensinogen synthesis. Objective: To evaluate antihypertensive efficacy and safety of different zilebesiran dosing regimens. Design, Setting, and Participants: This phase 2, randomized, double-blind, dose-ranging study of zilebesiran vs placebo was performed at 78 sites across 4 countries. Screening initiation occurred in July 2021 and the last patient visit of the 6-month study occurred in June 2023. Adults with mild to moderate hypertension, defined as daytime mean ambulatory systolic BP (SBP) of 135 to 160 mm Hg following antihypertensive washout, were randomized. Interventions: Randomization to 1 of 4 subcutaneous zilebesiran regimens (150, 300, or 600 mg once every 6 months or 300 mg once every 3 months) or placebo (once every 3 months) for 6 months. Main Outcomes and Measures: The primary end point was between-group difference in least-squares mean (LSM) change from baseline to month 3 in 24-hour mean ambulatory SBP. Results: Of 394 randomized patients, 377 (302 receiving zilebesiran and 75 receiving placebo) comprised the full analysis set (93 Black patients [24.7%]; 167 [44.3%] women; mean [SD] age, 57 [11] years). At 3 months, 24-hour mean ambulatory SBP changes from baseline were −7.3 mm Hg (95% CI, −10.3 to −4.4) with zilebesiran, 150 mg, once every 6 months; −10.0 mm Hg (95% CI, −12.0 to −7.9) with zilebesiran, 300 mg, once every 3 months or every 6 months; −8.9 mm Hg (95% CI, −11.9 to −6.0) with zilebesiran, 600 mg, once every 6 months; and 6.8 mm Hg (95% CI, 3.6-9.9) with placebo. LSM differences vs placebo in change from baseline to month 3 were −14.1 mm Hg (95% CI, −19.2 to −9.0; P <.001) with zilebesiran, 150 mg, once every 6 months; −16.7 mm Hg (95% CI, −21.2 to −12.3; P <.001) with zilebesiran, 300 mg, once every 3 months or every 6 months; and −15.7 mm Hg (95% CI, −20.8 to −10.6; P <.001) with zilebesiran, 600 mg, once every 6 months. Over 6 months, 60.9% of patients receiving zilebesiran had adverse events vs 50.7% patients receiving placebo and 3.6% had serious adverse events vs 6.7% receiving placebo. Nonserious drug-related adverse events occurred in 16.9% of zilebesiran-treated patients (principally injection site reactions and mild hyperkalemia) and 8.0% of placebo-treated patients. Conclusions and Relevance: In adults with mild to moderate hypertension, treatment with zilebesiran across a range of doses at 3-month or 6-month intervals significantly reduced 24-hour mean ambulatory SBP at month 3. Trial Registration: ClinicalTrials.gov Identifier: NCT04936035 This phase 2 randomized trial examines the antihypertensive efficacy and safety of different zilebesiran dosing regimens. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

121. Natural Language Processing for Adjudication of Heart Failure in a Multicenter Clinical Trial: A Secondary Analysis of a Randomized Clinical Trial.

Author

Cunningham, Jonathan W., Singh, Pulkit, Reeder, Christopher, Claggett, Brian, Marti-Castellote, Pablo M., Lau, Emily S., Khurshid, Shaan, Batra, Puneet, Lubitz, Steven A., Maddah, Mahnaz, Philippakis, Anthony, Desai, Akshay S., Ellinor, Patrick T., Vardeny, Orly, Solomon, Scott D., and Ho, Jennifer E.

Published
2024
Full Text
View/download PDF

122. Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan.

Author

Butt, Jawad H., McDowell, Kirsty, Kondo, Toru, Desai, Akshay S., Lefkowitz, Martin P., Packer, Milton, Petrie, Mark C., Pfeffer, Marc A., Rouleau, Jean L., Vaduganathan, Muthiah, Zile, Michael R., Jhund, Pardeep S., Køber, Lars, Solomon, Scott, and McMurray, John J.V.

Subjects
BRAIN natriuretic factor, ERYTHROCYTES, HEART failure, VENTRICULAR ejection fraction, VALSARTAN
Abstract

Aims: Red cell distribution width (RDW) is a strong prognostic marker in patients with heart failure (HF) and reduced ejection fraction and other conditions. However, very little is known about its prognostic significance in HF with preserved ejection fraction. We examined the relationship between RDW and outcomes and the effect of sacubitril/valsartan, compared with valsartan, on RDW and clinical outcomes in PARAGON‐HF. Methods and results: PARAGON‐HF enrolled patients with a left ventricular ejection fraction of ≥45%, structural heart disease, and elevated N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP). The primary endpoint was a composite of total HF hospitalizations and cardiovascular deaths. Median RDW at randomization was 14.1% (interquartile range 13.5–15.0%). Patients with higher RDW levels were more often men and had more comorbidity, a higher heart rate and NT‐proBNP concentration, more advanced New York Heart Association class, and worse Kansas City Cardiomyopathy Questionnaire scores. There was a graded relationship between quartiles of RDW at randomization and the primary endpoint, with a significantly higher risk associated with increasing RDW, even after adjustment for NT‐proBNP and other prognostic variables {Quartile 1, reference; Quartile 2, rate ratio 1.03 [95% confidence interval (CI) 0.83 to 1.28]; Quartile 3, 1.25 [1.01 to 1.54]; Quartile 4, 1.70 [1.39 to 2.08]}. This association was seen for each of the secondary outcomes, including cardiovascular and all‐cause death. Compared with valsartan, sacubitril/valsartan reduced RDW at 48 weeks [mean change −0.09 (95% CI −0.15 to −0.02)]. The effect of sacubitril/valsartan vs. valsartan was not significantly modified by RDW levels at randomization. Conclusions: RDW, a routinely available and inexpensive biomarker, provides incremental prognostic information when added to established predictors. Compared with valsartan, sacubitril/valsartan led to a small reduction in RDW. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

123. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER

Author

Kondo, Toru, primary, Butt, Jawad H., additional, Curtain, James P., additional, Jhund, Pardeep S., additional, Docherty, Kieran F., additional, Claggett, Brian L., additional, Vaduganathan, Muthiah, additional, Bachus, Erasmus, additional, Hernandez, Adrian F., additional, Lam, Carolyn S.P., additional, Inzucchi, Silvio E., additional, Martinez, Felipe A., additional, de Boer, Rudolf A., additional, Kosiborod, Mikhail N., additional, Desai, Akshay S., additional, Køber, Lars, additional, Ponikowski, Piotr, additional, Sabatine, Marc S., additional, Solomon, Scott D., additional, and McMurray, John J.V, additional

Published
2023
Full Text
View/download PDF

124. Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan

Author

Butt, Jawad H., primary, McDowell, Kirsty, additional, Kondo, Toru, additional, Desai, Akshay S., additional, Lefkowitz, Martin P., additional, Packer, Milton, additional, Petrie, Mark C., additional, Pfeffer, Marc A., additional, Rouleau, Jean L., additional, Vaduganathan, Muthiah, additional, Zile, Michael R., additional, Jhund, Pardeep S., additional, Køber, Lars, additional, Solomon, Scott, additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

125. As We Embark on a Second Year

Author

Bozkurt, Biykem, primary, Desai, Akshay S., additional, Ahmad, Tariq, additional, Deswal, Anita, additional, Heidenreich, Paul A., additional, Ibrahim, Nasrien E., additional, McMurray, John, additional, Pinney, Sean P., additional, Vaduganathan, Muthiah, additional, and Walsh, Mary Norine, additional

Published
2023
Full Text
View/download PDF

127. Calcium channel blocker and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

Author

Matsumoto, Shingo, primary, Kondo, Toru, additional, Yang, Mingming, additional, Campbell, Ross T, additional, Docherty, Kieran F., additional, de Boer, Rudolf A., additional, Desai, Akshay S., additional, Lam, Carolyn S.P., additional, Packer, Milton, additional, Pitt, Bertram, additional, Rouleau, Jean L., additional, Vaduganathan, Muthiah, additional, Zannad, Faiez, additional, Zile, Michael R., additional, Solomon, Scott D., additional, Jhund, Pardeep S., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

128. Impact of COVID‐19 in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Enrolled in the DELIVER Trial

Author

Bhatt, Ankeet S., primary, Kosiborod, Mikhail N., additional, Claggett, Brian L., additional, Miao, Zi Michael, additional, Vaduganathan, Muthiah, additional, Lam, Carolyn S.P., additional, Hernandez, Adrian F., additional, Martinez, Felipe A., additional, Inzucchi, Silvio E, additional, Shah, Sanjiv J., additional, de Boer, Rudolf A., additional, Jhund, Pardeep S., additional, Desai, Akshay S., additional, Fang, James C., additional, Han, Yaling, additional, Comin‐Colet, Josep, additional, Drożdż, Jarosław, additional, Vardeny, Orly, additional, Merkely, Bela, additional, Lindholm, Daniel, additional, Peterson, Magnus, additional, Langkilde, Anna Maria, additional, McMurray, John J.V., additional, and Solomon, Scott D., additional

Published
2023
Full Text
View/download PDF

130. Contemporary Use and Implications of Beta-blockers in Patients with HFmrEF or HFpEF: the DELIVER Trial

Author

Peikert, Alexander, primary, Bart, Bradley A., additional, Vaduganathan, Muthiah, additional, Claggett, Brian L., additional, Kulac, Ian J., additional, Kosiborod, Mikhail N., additional, Desai, Akshay S., additional, Jhund, Pardeep S., additional, Lam, Carolyn S.P., additional, Inzucchi, Silvio E., additional, Martinez, Felipe A., additional, de Boer, Rudolf A., additional, Hernandez, Adrian F., additional, Shah, Sanjiv J., additional, Petersson, Magnus, additional, Langkilde, Anna Maria, additional, McMurray, John J.V., additional, Solomon, Scott D., additional, and Vardeny, Orly, additional

Published
2023
Full Text
View/download PDF

131. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure

Author

Kondo, Toru, primary, Wang, Xiaowen, additional, Yang, Mingming, additional, Jhund, Pardeep S., additional, Claggett, Brian L., additional, Vaduganathan, Muthiah, additional, Hernandez, Adrian F., additional, Lam, Carolyn S.P., additional, Inzucchi, Silvio E., additional, Martinez, Felipe A., additional, de Boer, Rudolf A., additional, Kosiborod, Mikhail N., additional, Desai, Akshay S., additional, Køber, Lars, additional, Ponikowski, Piotr, additional, Sabatine, Marc S., additional, Langkilde, Anna Maria, additional, Petersson, Magnus, additional, Zaozerska, Natalia, additional, Bachus, Erasmus, additional, Solomon, Scott D., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

132. Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial

Author

Pabon, Maria, primary, Claggett, Brian L., additional, Wang, Xiaowen, additional, Miao, Zi Michael, additional, Chatur, Safia, additional, Bhatt, Ankeet S., additional, Vaduganathan, Muthiah, additional, Fang, James C., additional, Desai, Akshay S, additional, Jhund, Pardeep, additional, Martinez, Felipe, additional, de Boer, Rudolf A., additional, Kosiborod, Mikhail N., additional, Lam, Carolyn S.P., additional, Shah, Sanjiv J., additional, Hernandez, Adrian F., additional, McMurray, John J.V., additional, Solomon, Scott D., additional, and Vardeny, Orly, additional

Published
2023
Full Text
View/download PDF

139. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

Author

Fitter, Heather D., Illoh, Kachikwu, Cavanaugh, Kenneth J., Jr., Scirica, Benjamin M., Irony, Ilan, Brown Kichline, Rachel E., Levine, Jonathan G., Park, Anna, Sacks, Leonard, Szarfman, Ana, Unger, Ellis F., Wachter, Lori Ann, Zuckerman, Bram, Mitchel, Yale, Peddicord, Douglas, Shook, Thomas, Kisler, Bron, Jaffe, Charles, Bartley, Rhonda, DeMets, David L., Mencini, MariJo, Janning, Cheri, Bai, Steve, Lawrence, John, D’Agostino, Ralph B., Sr., Pocock, Stuart J., Hicks, Karen A., Mahaffey, Kenneth W., Mehran, Roxana, Nissen, Steven E., Wiviott, Stephen D., Dunn, Billy, Solomon, Scott D., Marler, John R., Teerlink, John R., Farb, Andrew, Morrow, David A., Targum, Shari L., Sila, Cathy A., Thanh Hai, Mary T., Jaff, Michael R., Joffe, Hylton V., Cutlip, Donald E., Desai, Akshay S., Lewis, Eldrin F., Gibson, C. Michael, Landray, Martin J., Lincoff, A. Michael, White, Christopher J., Brooks, Steven S., Rosenfield, Kenneth, Domanski, Michael J., Lansky, Alexandra J., McMurray, John J.V., Tcheng, James E., Steinhubl, Steven R., Burton, Paul, Mauri, Laura, O’Connor, Christopher M., Pfeffer, Marc A., Hung, H.M. James, Stockbridge, Norman L., Chaitman, Bernard R., and Temple, Robert J.

Published
2018
Full Text
View/download PDF

140. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF

Author

Jhund, Pardeep S., Solomon, Scott D., Docherty, Kieran F., Heerspink, Hiddo J.L., Anand, Inder S., Böhm, Michael, Chopra, Vijay, de Boer, Rudolf A., Desai, Akshay S., Ge, Junbo, Kitakaze, Masafumi, Merkley, Bela, OʼMeara, Eileen, Shou, Morten, Tereshchenko, Sergey, Verma, Subodh, Vinh, Pham Nguyen, Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Bengtsson, Olof, Langkilde, Anna Maria, Sjöstrand, Mikaela, and McMurray, John J.V.

Published
2021
Full Text
View/download PDF

142. Knowledge about self‐efficacy and outcomes in patients with heart failure and reduced ejection fraction

Author

Yang, Mingming, primary, Kondo, Toru, additional, Adamson, Carly, additional, Butt, Jawad H., additional, Abraham, William T., additional, Desai, Akshay S., additional, Jering, Karola S., additional, Køber, Lars, additional, Kosiborod, Mikhail N., additional, Packer, Milton, additional, Rouleau, Jean L., additional, Solomon, Scott D., additional, Vaduganathan, Muthiah, additional, Zile, Michael R., additional, Jhund, Pardeep S., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

143. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

Author

Desai, Akshay S., primary, Webb, David J., additional, Taubel, Jorg, additional, Casey, Sarah, additional, Cheng, Yansong, additional, Robbie, Gabriel J., additional, Foster, Don, additional, Huang, Stephen A., additional, Rhyee, Sean, additional, Sweetser, Marianne T., additional, and Bakris, George L., additional

Published
2023
Full Text
View/download PDF

144. Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with HFrEF and HFpEF

Author

Yang, Mingming, primary, Kondo, Toru, additional, Adamson, Carly, additional, Butt, Jawad H., additional, Abraham, William T., additional, Desai, Akshay S., additional, Jering, Karola S., additional, Køber, Lars, additional, Kosiborod, Mikhail N., additional, Packer, Milton, additional, Rouleau, Jean L., additional, Solomon, Scott D., additional, Vaduganathan, Muthiah, additional, Zile, Michael R., additional, Jhund, Pardeep S., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

145. Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Author

Peikert, Alexander, primary, Chandra, Alvin, additional, Kosiborod, Mikhail N., additional, Claggett, Brian L., additional, Desai, Akshay S., additional, Jhund, Pardeep S., additional, Lam, Carolyn S. P., additional, Inzucchi, Silvio E., additional, Martinez, Felipe A., additional, de Boer, Rudolf A., additional, Hernandez, Adrian F., additional, Shah, Sanjiv J., additional, Janssens, Stefan P., additional, Bělohlávek, Jan, additional, Borleffs, C. Jan Willem, additional, Dobreanu, Dan, additional, Langkilde, Anna Maria, additional, Bengtsson, Olof, additional, Petersson, Magnus, additional, McMurray, John J. V., additional, Solomon, Scott D., additional, and Vaduganathan, Muthiah, additional

Published
2023
Full Text
View/download PDF

146. Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial

Author

Chatur, Safia, primary, Cunningham, Jonathan W., additional, Vaduganathan, Muthiah, additional, Mc Causland, Finnian R., additional, Claggett, Brian L., additional, Desai, Akshay S., additional, Miao, Zi Michael, additional, Jhund, Pardeep S., additional, de Boer, Rudolf A., additional, Hernandez, Adrian F., additional, Inzucchi, Silvio E., additional, Kosiborod, Mikhail N., additional, Lam, Carolyn S.P., additional, Martinez, Felipe A., additional, Shah, Sanjiv J., additional, Petersson, Magnus, additional, Langkilde, Anna Maria, additional, McMurray, John J.V., additional, and Solomon, Scott D., additional

Published
2023
Full Text
View/download PDF

147. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the DAPA‐HF and DELIVER trials

Author

Bhatt, Ankeet S., primary, Kosiborod, Mikhail N., additional, Vaduganathan, Muthiah, additional, Claggett, Brian L., additional, Miao, Z. Michael, additional, Kulac, Ian J., additional, Lam, Carolyn S.P., additional, Hernandez, Adrian F., additional, Martinez, Felipe, additional, Inzucchi, Silvio E, additional, Shah, Sanjiv J., additional, de Boer, Rudolf A., additional, Jhund, Pardeep S., additional, Desai, Akshay S., additional, Petersson, Magnus, additional, Langkilde, Anna Maria, additional, McMurray, John J.V., additional, and Solomon, Scott D., additional

Published
2023
Full Text
View/download PDF

148. Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER

Author

Butt, Jawad H, primary, Kondo, Toru, additional, Yang, Mingming, additional, Jhund, Pardeep S, additional, Docherty, Kieran F, additional, Vaduganathan, Muthiah, additional, Claggett, Brian L, additional, Hernandez, Adrian F, additional, Lam, Carolyn S P, additional, Inzucchi, Silvio E, additional, Martinez, Felipe A, additional, de Boer, Rudolf A, additional, Kosiborod, Mikhail N, additional, Desai, Akshay S, additional, Køber, Lars, additional, Ponikowski, Piotr, additional, Sabatine, Marc S, additional, Shah, Sanjiv J, additional, Zaozerska, Natalia, additional, Wilderäng, Ulrica, additional, Bengtsson, Olof, additional, Solomon, Scott D, additional, and McMurray, John J V, additional

Published
2023
Full Text
View/download PDF

149. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

Author

Chatur, Safia, primary, Vaduganathan, Muthiah, additional, Claggett, Brian, additional, Vardeny, Orly, additional, Desai, Akshay S, additional, Jhund, Pardeep S, additional, de Boer, Rudolf A, additional, Lam, Carolyn S P, additional, Kosiborod, Mikhail N, additional, Shah, Sanjiv J, additional, Martinez, Felipe, additional, Inzucchi, Silvio E, additional, Hernandez, Adrian F, additional, Haddad, Tariq, additional, Mitter, Sumeet S, additional, Miao, Zi Michael, additional, Petersson, Magnus, additional, Maria Langkilde, Anna, additional, McMurray, John J V, additional, and Solomon, Scott D, additional

Published
2023
Full Text
View/download PDF

150. Effects of Dapagliflozin on Heart Failure Hospitalizations According to Severity of Inpatient Course: Insights from DELIVER and DAPA‐HF

Author

Chatur, Safia, primary, Kondo, Toru, additional, Claggett, Brian L., additional, Docherty, Kieran, additional, Miao, Zi Michael, additional, Desai, Akshay S., additional, Jhund, Pardeep S., additional, de Boer, Rudolf A., additional, Hernandez, Adrian F., additional, Inzucchi, Silvio E., additional, Kosiborod, Mikhail N, additional, Lam, Carolyn S. P., additional, Martinez, Felipe A., additional, Shah, Sanjiv J., additional, Petersson, Magnus, additional, Langkilde, Anna Maria, additional, McMurray, John J.V., additional, Solomon, Scott D., additional, and Vaduganathan, Muthiah, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results